New Genetic Markers and Vitamin B3 Offer Hope in Managing MASLD Progression
Researchers identify a genetic regulator, microRNA-93, that worsens MASLD, with vitamin B3 showing promise as an effective treatment to counteract disease progression.
Approximately 30% of the global population suffers from metabolic-associated fatty liver disease (MASLD), a condition previously lacking specific targeted treatments. Recent research has uncovered a genetic factor that contributes to the worsening of MASLD, highlighting the role of microRNA-93 (miR-93) in disease progression. This liver-expressed microRNA promotes lipid accumulation, inflammation, and fibrosis by inhibiting SIRT1, a critical gene involved in lipid metabolism.
A collaborative effort led by Professor Jang Hyun Choi from UNIST, alongside counterparts from Pusan National University and Ulsan University Hospital, revealed that elevated levels of miR-93 are found in both patients with fatty liver disease and relevant animal models. Molecular studies demonstrated that reducing miR-93 levels in mice resulted in decreased hepatic fat accumulation and improved insulin sensitivity and liver function. Conversely, overexpression of miR-93 exacerbated liver metabolic dysfunction.
Strikingly, drug screening identified niacin (vitamin B3) as the most effective FDA-approved medication to suppress miR-93. Treatment with niacin significantly lowered liver miR-93 levels and increased SIRT1 activity, which restored lipid metabolic pathways and helped normalize liver lipid balance. This suggests that niacin, a well-established medication, could be repurposed as a therapeutic agent for MASLD through modulation of this genetic pathway.
The findings underscore the potential of targeting specific microRNAs to treat fatty liver disease and demonstrate how an existing safe medication like vitamin B3 could be integrated into new treatment strategies. This research opens promising avenues for personalized therapy in MASLD, emphasizing the importance of molecular genetics in disease management.
Published in the journal Metabolism, the study highlights the clinical relevance of repurposing known drugs for new indications and provides a foundation for future therapeutic development in fatty liver disease.
Source: https://medicalxpress.com/news/2025-05-genetic-factor-worsening-masld-vitamin.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Preclinical Research Uncovers Secret Behind Rapid Oral Wound Healing
A new preclinical study uncovers the cellular mechanisms that enable the mouth to heal wounds rapidly and without scarring, paving the way for regenerative skin treatments.
Impact of Neighborhood Marginalization on Outcomes After Heart Attack in Young Adults
Living in socioeconomically marginalized neighborhoods is associated with higher mortality and reduced healthcare follow-up in young acute myocardial infarction survivors, emphasizing the impact of social determinants on heart health outcomes.
Oxidative Stress May Inhibit Cancer Development in People with BRCA2 Gene Variants
A groundbreaking study reveals that oxidative stress may suppress cancer in individuals with BRCA2 gene mutations, offering new insights into cancer prevention strategies.
Breakthrough in Primate Stem Cell Research: Adult Cells Identified in Small Non-Human Primate
Scientists have uncovered adult stem cells in a small non-human primate, the mouse lemur, offering promising new avenues for regenerative medicine and muscle disease treatments. This discovery enhances our understanding of primate biology and improves the development of human therapies.